Novavax (NVAX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $85 million, with $38 million from product sales and $46 million from licensing, royalties, and other revenue, mainly from the Sanofi partnership.

• Net loss for Q3 2024 was $121 million ($0.76 per share), improved from $131 million ($1.26 per share) in Q3 2023, driven by lower R&D and SG&A expenses.

• The Sanofi partnership brought a $500 million upfront payment, $70 million equity investment, and up to $700 million in future milestones, with Sanofi assuming lead commercial responsibility for Nuvaxovid in major markets for 2025–2026.

• Cost restructuring and workforce reductions led to a 26% decrease in combined R&D and SG&A expenses year-over-year for Q3 2024.

• FDA removed clinical hold on COVID-19-Influenza Combination and stand-alone influenza vaccine candidates, enabling advancement to Phase 3 trials.

Financial highlights

• Q3 2024 total revenue was $85 million, down from $187 million in Q3 2023.

• Q3 2024 product sales were $38 million, up from $2 million in Q3 2023, driven by higher U.S. sales.

• Q3 2024 cost of sales was $61 million, including $28 million related to excess, obsolete, or expired inventory.

• R&D expenses decreased to $87 million and SG&A expenses to $71 million in Q3 2024.

• Cash, cash equivalents, marketable securities, and restricted cash totaled $924 million as of September 30, 2024, up from $584 million at year-end 2023.

Outlook and guidance

• Full-year 2024 revenue guidance updated to $650–$700 million, with product sales of $175–$225 million and licensing, royalties, and other revenue of $475 million.

• Combined R&D and SG&A expense guidance maintained at $700–$750 million for 2024, targeting $350 million by 2026.

• Additional cost reduction programs planned for 2025–2026, with some expenses to be reimbursed by Sanofi.

• Sufficient capital is expected to fund operations for at least one year.